Medicine and Dentistry
Pediatrics
100%
Liver Disease
91%
Cystic Fibrosis
70%
Hepatitis C
61%
Ascites
37%
Infection
29%
Liver Transplantation
28%
Pediatrics Patient
26%
Antivirus Agent
25%
Hepatitis C Virus
25%
Transplantation
22%
Alagille Syndrome
20%
Hepatitis E Virus
20%
Liver Cirrhosis
19%
Platelet
18%
Hepatitis B Virus
17%
Prospective Study
17%
Virus Infection
16%
Biological Marker
16%
Liver Graft
16%
Portal Hypertension
15%
Disease
15%
Hepatitis B
14%
Gastrointestinal Distress
14%
Hepatitis E
13%
Bile Acid
13%
Acute Liver Failure
13%
Vanishing Bile Duct Syndrome
13%
Scoring System
13%
Autoimmune Hepatitis
13%
Kidney Graft
13%
Virus
13%
Retrospective Study
13%
Posttransplant Lymphoproliferative Disease
12%
Bleeding
11%
Liver Biopsy
11%
Transient Elastography
10%
Chronic Liver Disease
10%
Magnetic Resonance Imaging
10%
Clinician
10%
Biliary Atresia
10%
Abdominal Pain
10%
Pruritus
9%
Symptom
9%
Hypoglycemia
9%
Ribavirin
9%
Antiviral Therapy
9%
Serum Albumin
8%
Fatty Liver
8%
Fibrosis
8%
Keyphrases
Cystic Fibrosis
56%
Ultrasound
49%
United States
44%
Hepatitis C
36%
Hospitalization
35%
Hepatitis C Virus
34%
Pediatric Patients
33%
Liver
32%
Ascites
30%
Hepatitis E Virus
27%
Hepatitis E Virus Infection
26%
Polycystic Liver Disease
26%
Liver Disease
25%
Hepatitis C Virus Infection
25%
Risk Factors
24%
Pediatric
23%
Cirrhosis
22%
Infections in children
21%
Ultrasound Pattern
20%
Advanced Liver Disease
20%
Direct-acting Antivirals
20%
Pregnant Women
18%
Liver Ultrasound
15%
Virus
15%
Alagille Syndrome
15%
Hepatitis E
14%
Natural History
13%
Pediatric Liver Disease
13%
North America
13%
High Risk
13%
Vanishing Bile Duct Syndrome
13%
Liver Outcomes
13%
Kidney Transplant Recipients
13%
National Cohort Study
13%
Pediatric Donor
13%
Liver Transplantation
12%
Hepatitis B
12%
Adulthood
12%
Health-related Quality of Life
12%
Epidemiology
11%
Varicella
11%
Native Liver Survival
11%
Native Liver
10%
HCV Infection
10%
Hepatitis A
10%
Etiology
9%
Hospitalization Rate
9%
Genotype
9%
Pediatric Population
9%
Biliary Diversion
9%
Pharmacology, Toxicology and Pharmaceutical Science
Hepatitis C
68%
Infection
40%
Cystic Fibrosis
33%
Antivirus Agent
33%
Liver Disease
31%
Hepatitis C Virus
28%
Hepatitis E Virus
28%
Alagille Syndrome
27%
Hepatitis E
24%
Virus Infection
23%
Hepatitis B Virus
20%
Hepatitis B
15%
Disease
14%
Bile Acid
13%
Clinical Trial
12%
Pruritus
11%
Portal Hypertension
11%
Survival Rate
10%
Liver Cirrhosis
9%
Vertical Transmission
9%
Adverse Event
9%
Ascites
9%
Chronic Hepatitis C
8%
Hepatitis E Vaccine
8%
Digestive System Cancer
8%
Event Free Survival
7%
Virus Hepatitis
7%
Placebo
7%
Malignant Neoplasm
7%
Biological Marker
7%
Syndrome
7%
Alpha Antitrypsin Deficiency
6%
Inflammatory Bowel Disease
6%
Live Vaccine
6%
Mumps
6%
Acute Liver Failure
6%
Toxic Hepatitis
6%
Eosinophilic Gastrointestinal Disorder
6%
Hepatitis C Virus Genotype 6
6%
microRNA
6%
Lymphoproliferative Disease
6%
Tacrolimus
6%
Rubella
6%
Delta Agent Hepatitis
6%
Chickenpox
6%
Chilaiditi Syndrome
6%
Maralixibat
6%
Tenofovir Disoproxil
6%
Tenofovir Alafenamide
6%
Chronic Hepatitis B
6%